Menu Search
Equities

Genor Biopharma Holdings Ltd

67N0:DUS

Genor Biopharma Holdings Ltd

Actions
  • Price (EUR)0.20
  • Today's Change-0.002 / -0.99%
  • Shares traded0.00
  • 1 Year change+41.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Genor Biopharma Holdings Ltd had revenues fall -100.00% from 15.93m to 0.00, though the company grew net income from a loss of 730.21m to a smaller loss of 674.36m.
Gross margin97.59%
Net profit margin-3,638.27%
Operating margin-3,769.79%
Return on assets-33.87%
Return on equity-40.03%
Return on investment-39.06%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Genor Biopharma Holdings Ltd fell by 423.22m. However, Cash Flow from Investing totalled 5.99m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 425.12m for operations while cash used for financing totalled 6.82m.
Cash flow per share-0.994
Price/Cash flow per share--
Book value per share2.24
Tangible book value per share2.02
More ▼

Balance sheet in CNYView more

Genor Biopharma Holdings Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio5.76
Quick ratio5.73
Total debt/total equity0.003
Total debt/total capital0.003
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.